Centessa Pharmaceuticals (CNTA): Truist sees 88% price potential - ORX750 offers potential in narcolepsy and idiopathic hypersomnia
Reading Time: 3 minutes
The centerpiece in the pipeline of Centessa Pharmaceuticals (CNTA) is the Orexin Receptor-2 (OX2R) agonist program with the main candidates ORX750 and ORX142. ORX750 is currently in Phase 1 of development and is being investigated for the treatment of Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH). These indications represent chronic neurological disorders that significantly impair the quality of life of those affected and for which there is still a considerable need for effective and well-tolerated therapies....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
